Mr. Speaker, drug compounding companies are not federally regulated like drug manufacturers, nor provincially regulated like pharmacies. In the Marchese case, an error by a compounder resulted in cancer patients receiving diluted doses of a chemotherapy drug. The Obama administration has brought compounders under federal law, treating these companies more like drug manufacturers. Will the government apply federal standards for drug manufacturers to compounding companies to avoid a balkanized regulatory regime that varies from province to province?
In the House of Commons on January 31st, 2014. See this statement in context.